
TVGN Stock Forecast & Price Target
TVGN Analyst Ratings
Bulls say
Tevogen Bio Holdings is facing multiple factors that have led to a lowering of their price target and a change in rating from Buy to Hold. However, they recently announced a clinical milestone that expands their target coverage, increasing their potential patient access and enhancing the reach of their lead product candidate (TVGN 489) in both acute COVID-19 and Long COVID populations. Despite some risk factors, such as Clinical/Regulatory Risk, Partnership and Financial Risk, Commercial Risk, Legal and Intellectual Property Risk, and Market Share Risk, Tevogen Bio Holdings has a promising future with their expanding technology platform and potential in treating infectious diseases, cancers, and neurological disorders.
Bears say
Tevogen Bio Holdings is facing a significant risk of dilution as a result of its low stock price, hindering its ability to attract and retain investors and potentially impacting its financial stability and ability to advance its ExacTcell platform and develop its first clinical product TVGN 489. Additionally, the company is facing various risks in its operations, including clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share risks, which could impact its potential for success in the competitive healthcare industry. The company has also faced a decrease in its financial performance, lowering its price target from $5.0 to $2.0, reinforcing our negative outlook on the company's trajectory.
This aggregate rating is based on analysts' research of Semper Paratus Acquisition Corp and is not a guaranteed prediction by Public.com or investment advice.
TVGN Analyst Forecast & Price Prediction
Start investing in TVGN
Order type
Buy in
Order amount
Est. shares
0 shares